Cargando…
Feasibility of recruiting high-risk women in the US for HIV vaccine efficacy trials (HVTN 906)
Autores principales: | Koblin, B, Metch, B, Morgan, C, Novak, R, Swann, E, Metzger, D, Lucy, D, Dunbar, D, Graham, P, Madenwald, T, Escamia, G, Frank, I |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441717/ http://dx.doi.org/10.1186/1742-4690-9-S2-P123 |
Ejemplares similares
-
P15-08. Did unblinding affect HIV risk behaviour and risk perception in the HVTN503/Phambili study?
por: Gray, GE, et al.
Publicado: (2009) -
P15-15. Advocates' perspectives on community engagement in the HVTN 505
por: Warren, M, et al.
Publicado: (2009) -
P15-13. HVTN 503(Phambili) trial discontinuation of enrolment/vaccination: the impact on trial participant attitudes to vaccine trials and scientific research
por: Mark, D, et al.
Publicado: (2009) -
HIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials
por: Volk, JE, et al.
Publicado: (2012) -
P13-05. Factors associated with pregnancy during the HVTN 503/Phambili trial, a phase IIB HIV trial of the Merck Ad-5 multi-clade HIV vaccine
por: Latka, M, et al.
Publicado: (2009)